Optimed Research, LTD | The Boster Center for Multiple Sclerosis
Site insights
Top conditions
Top treatments
Parent organization
This site is a part of Optimed Research, LTD
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the effic...
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the effic...
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizuma...
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...
This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment.The purpose of this study is to evaluate SC administration of fre...
Trial sponsors
Clinical trials
Research sites
Resources
Legal